- Home
- / Soleno Therapeutics
Soleno Therapeutics
Stock Price
$56.3
2024-10-29
Market Capitalization
$2.2 B
2024-10-29
Revenue
$190.4 M
FY, 2025
Soleno Therapeutics Summary
Company Summary
- Overview
- Soleno Therapeutics (formerly known as Capnia) is a biopharmaceutical company that develops solutions for treating rare diseases. It offers Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for treating Prader-Willi syndrome.
- Type
- Public
- Status
- Active
- Founded
- 1999
- HQ
- Redwood City, CA, US | view all locations
- Website
- https://soleno.life/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Jim Mackaness, Chief Financial Officer
Neil M. Cowen, Senior Vice President of Drug Development
Kristen Yen, Vice President, Clinical Operations
LocationsView all
1 location detected
Redwood City, CA HQ
United States
100 Marine Pkwy Suite 400
Soleno Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $94.6M
- Gross profit (Q1, 2026)
- $93.4M
- Net income (Q1, 2026)
- $31.4M
- Cash (Q1, 2026)
- $133.0M
- EBIT (Q1, 2026)
- $31.3M
- Enterprise value
- $2.1B